STOCK TITAN

Nervgen Pharma Corp - NGENF STOCK NEWS

Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.

NervGen Pharma Corp (NGENF) is a clinical-stage biotechnology company advancing novel therapies for nervous system repair. This page provides investors and medical professionals with timely updates on clinical trials, regulatory milestones, and strategic developments.

Access comprehensive coverage of NervGen's progress including NVG-291 Phase 1b/2a trial updates, preclinical research for NVG-300, financial disclosures, and partnership announcements. Our curated news collection enables efficient tracking of both scientific advancements and corporate initiatives in neurorestoration.

Key updates focus on spinal cord injury treatment developments, biomarker validation studies, and operational strategies addressing clinical trial recruitment challenges. Content spans press releases, peer-reviewed findings, and market-sensitive announcements while maintaining compliance with financial disclosure standards.

Bookmark this page for streamlined access to NervGen's evolving story in neurorestorative therapeutics. Check regularly for authoritative reporting on trial outcomes, pipeline expansions, and strategic positioning within the competitive biotech landscape.

Rhea-AI Summary
NervGen Pharma to present at H.C. Wainwright conference, offering one-on-one investor meetings. Webcast available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
conferences
-
Rhea-AI Summary
NervGen Pharma to present at KOL Discussion on Spinal Cord Injury
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
Rhea-AI Summary
NervGen Pharma Corp. reports financial and operational results for Q2 2023. Landmark Phase 1a/2b clinical trial of NVG-291 for spinal cord injury proceeds with recruitment. Results expected in mid-2024. Mike Kelly appointed as President & CEO. Grant of up to US$3.18 million awarded from Wings for Life to support clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
Rhea-AI Summary
NervGen Pharma Corp. has extended the expiry date of certain stock options granted to a consultant, from three years to five years following the original grant dates. The exercise price and other terms of the options remain unchanged.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
Nervgen Pharma Corp

OTC:NGENF

NGENF Rankings

NGENF Stock Data

132.38M
54.82M
22.76%
Biotechnology
Healthcare
Link
Canada
Vancouver